immunotherapies

Immunohistochemistry (IHC) is referred to as the study of a branch of chemistry including the study of various components and functions of the immune system with the application of antigen & antibodies as chemical reagents. It is a technique that combines anatomy, physiology, immunology and biochemistry.  It involves the use of simple, rapid, and robust […]

News round-up by DDW’s Reece Armstrong for 23-27 May   UK investment plans, company appointments to drive strategy, and digital health platforms are some of the themes of this week’s news round-up.    New £20m fund launches to support North West life sciences  A new £20 million fund has been launched in the Northwest of England to […]

DDW Deputy Editor Reece Armstrong speaks to Professor Frederic Triebel, CSO of Immutep about the approval of Bristol Myers Squibb’s LAG-3 antibody and why it’s causing so much excitement in the sector.    Recently, the Food and Drug Administration (FDA) approved the first combination therapy to block the immune checkpoint receptor protein LAG-3 – a move which is […]

Ilya Pharma, a clinical stage immunotherapy company, has closed a €8.5 million funding round, which will be used to advance the company’s portfolio of three first-in-class immunotherapies for skin and mucosal diseases.   The portfolio   The active portfolio includes ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic […]

Chimeric Antigen Receptor or CAR-T cells, a new form of immunotherapy with genetically engineered immune system cells, has been approved for the treatment of multiple myeloma, a type of blood cancer.  Context  In a case study published in Nature Medicine, Sinai scientists reported a previously unknown neurological side effect resembling symptoms Parkinson’s Disease in a patient […]

Combination immunotherapies are one of the most exciting advanced therapy medicinal products (ATMP) being developed, with incredible potential for treating cancer, says Panagiotis Parsonidis, a molecular biologist and lead researcher at RGCC. DDW speaks to him about VAXO-Q-RE developments, a combination immunotherapy that will soon enter clinical trials.  VAXO-Q-RE is an advanced combination immunotherapy that consists of […]

eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, has opened a subsidiary, eTheRNA Asia, with offices located in the Sheung Wan area of Hong Kong. The Asia-Pacific region is growing in importance in the global healthcare sector and this new subsidiary will serve as a focus for […]

Ixaka and SomaLogic have created a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer reagents (modified aptamers that bind tightly and specifically to protein targets) previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamers. Ixaka is […]

In the last decade, cancer immunotherapy has emerged as one the most promising treatments for the disease. In a recent pilot study, Professor Joachim Drevs and his co-authors; Joachim Ahlers, Eglys Gonzalez Marcano and Leona Kröhle describe how a new autologous vaccine developed in partnership with cancer clinic RGCC created a confirmed anti-tumour response in […]

An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health (NIH). The researchers found that 48 of 50 children who received the gene therapy retained their replenished immune system function two […]